Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
How Metformin Influences Breast Cancer Risk
Letter from the Editor
There is plenty of evidence that most patients use apps on their phones to keep track of almost everything in their lives. There are apps for steps and apps for yoga, there are apps for banking and apps for investing. Don’t forget the apps for applying make-up properly or for selling your used clothes, or betting on horse races — and even for making a call.
The use of apps has become so common that it is now much easier to convince a patient to use an app to manage their health, including how they are doing with gestational diabetes.
This week our intern, Mia Flowers, PharmD Candidate from FAMU College of pharmacy, shares the results of a wide ranging study looking at the use of mobile devices to help manage gestational diabetes and why tight control is a definite plus for both mom and the newborn.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
Newsflash: Blockbuster T2D Drug Lowers A1c Below 5.7% And Provides A 27 LB Wt. Loss
See this week’s Did You Know?
TOP STORIES — Diabetes News and Research
Study examines the complex relationship between type 2 diabetes, metformin use, and breast cancer subtype.
Researchers sought to assess the prevalence and trend of diabetic complications in adult patients over thirty years.
Clinical dietitians and mobile apps play a crucial role in personalizing treatment for patients with gestational diabetes.
Did You Know? Blockbuster Drug Soon to Be Approved for T2D
Tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor, is in phase 3 development for blood glucose management in adults with type 2 diabetes and for chronic weight management.
In Eli Lilly and Company’s 40-week SURPASS-2 clinical trial, tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults with type 2 diabetes. In topline results from the largest SURPASS trial to date, using the efficacy estimandi, the highest dose of tirzepatide (15 mg) reduced A1C by 2.46 percent and body weight by 12.4 kg (27.3 lb., 13.1 percent). The lowest dose of tirzepatide (5 mg) reduced A1C by 2.09 percent and body weight by 7.8 kg (17.2 lb., 8.5 percent) compared to semaglutide at 1.86 percent and 6.2 kg (13.7 lb., 6.7 percent).
Additionally, 51 percent of those taking tirzepatide 15 mg achieved an A1C of less than 5.7 percent – the level seen in people without diabetes – compared to 20 percent of those taking semaglutide. The overall safety profile of tirzepatide was similar to previously reported SURPASS trials and the well-established glucagon-like peptide-1 (GLP-1) receptor agonist class. Across all treatment arms, the most commonly reported adverse events were gastrointestinal-related.
Lilly News Release
HCP Live
Steve Freed, R.Ph., Publisher, CDE
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:
Tarshay Boyd, PharmD. Candidate, LECOM School of Pharmacy
Mia Flowers, PharmD. Candidate of Florida Agricultural & Mechanical University School of Pharmacy
Macrina Ghali, PharmD Candidate 2021, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences
Emmanuel Obi, PharmD Candidate, Lake Erie College of Osteopathic Medicine (LECOM), School of Pharmacy, Bradenton, Florida
Sandra Zaki, PharmD Candidate, Florida A&M University
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com